Hsieh HL, Tsai MM. Tumor progression-dependent angiogenesis in gastric cancer and its potential application. World J Gastrointest Oncol 2019; 11(9): 686-704 [PMID: 31558974 DOI: 10.4251/wjgo.v11.i9.686]
Corresponding Author of This Article
Ming-Ming Tsai, PhD, Associate Professor, Department of Nursing, Division of Basic Medical Sciences, Chang-Gung University of Science and Technology, 261 Wen-hwa 1 Road, Taoyuan 333, Taiwan. mmtsai@mail.cgust.edu.tw
Research Domain of This Article
Oncology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Hsieh HL, Tsai MM. Tumor progression-dependent angiogenesis in gastric cancer and its potential application. World J Gastrointest Oncol 2019; 11(9): 686-704 [PMID: 31558974 DOI: 10.4251/wjgo.v11.i9.686]
World J Gastrointest Oncol. Sep 15, 2019; 11(9): 686-704 Published online Sep 15, 2019. doi: 10.4251/wjgo.v11.i9.686
Tumor progression-dependent angiogenesis in gastric cancer and its potential application
Hsi-Lung Hsieh, Ming-Ming Tsai
Hsi-Lung Hsieh, Ming-Ming Tsai, Research Center for Chinese Herbal Medicine, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan 333, Taiwan
Hsi-Lung Hsieh, Ming-Ming Tsai, Department of Nursing, Division of Basic Medical Sciences, Chang-Gung University of Science and Technology, Taoyuan 333, Taiwan
Hsi-Lung Hsieh, Department of Neurology, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan
Ming-Ming Tsai, Department of General Surgery, Chang Gung Memorial Hospital, Chiayi 613, Taiwan
Author contributions: The author contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.
Supported bythe Ministry of Science and Technology, Taiwan, No. MOST 106-2320-B-255-005 and No. MOST 107-2320-B-255-003; Chang Gung Medical Research Foundation, Taoyuan, Taiwan, No. CMRPF1G0011, No. CMRPF1G0251, No. CMRPF1I0031, No. CMRPF1H0051, and No. CMRPF1I0041; and Chang Gung University of Science and Technology, Taoyuan, Taiwan, No. ZRRPF3H0131.
Conflict-of-interest statement: No potential conflicts of interest. No financial support.
Corresponding author: Ming-Ming Tsai, PhD, Associate Professor, Department of Nursing, Division of Basic Medical Sciences, Chang-Gung University of Science and Technology, 261 Wen-hwa 1 Road, Taoyuan 333, Taiwan. mmtsai@mail.cgust.edu.tw
Telephone: +886-3-2118999 Fax: +886-3-2118866
Received: March 15, 2019 Peer-review started: March 18, 2019 First decision: June 5, 2019 Revised: July 5, 2019 Accepted: August 19, 2019 Article in press: August 19, 2019 Published online: September 15, 2019 Processing time: 181 Days and 18.6 Hours
Core Tip
Core tip: Tumor angiogenesis in gastric cancer (GC) and antiangiogenic therapies for GC, including information from their preclinical and/or application to clinical trials, are discussed. The antiangiogenic strategies for advanced GC include decreasing the expression of proangiogenic ligands and their receptors, increasing the level of angiogenic inhibitors, and directly targeting the inner walls of endothelial cells. Here, the antiangiogenic strategies mainly focus on decreasing the expression of vascular endothelial growth factor-mediated pathway constituents for advanced GC in phase III clinical trials. Thus, this review provides a brief description of various tumor angiogenic factors for the purposes of diagnosis, prognosis and therapeutics and describes the antiangiogenic agents that are currently being investigated in preclinical and phase III clinical trials. Hopefully, according to the molecular mechanism of tumor angiogenesis, we highlight the accuracy of the diagnosis and prognosis and the selection of the most appropriate therapy for GC patients.
